Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe. Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes ...